Quick Answer
Aspira Women’s Health Inc. reported R&D Expense of $3.27 million for fiscal year 2024.
Aspira Women’s Health Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $3.27M | -19.1% |
| 2023 | $4.04M | -31.8% |
| 2022 | $5.92M | +11.3% |
| 2021 | $5.31M | +152.6% |
| 2020 | $2.10M | +106.7% |
| 2019 | $1.02M | +85.1% |
| 2018 | $550.0K | -34.3% |
| 2017 | $837.0K | -61.5% |
| 2016 | $2.17M | -42.1% |
| 2015 | $3.75M | -19.6% |
| 2014 | $4.67M | +79.8% |
| 2013 | $2.60M | +17.1% |
| 2012 | $2.22M | -58.9% |
| 2011 | $5.39M | +40.0% |
| 2010 | $3.85M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $739.0K | -18.6% | +5.0% |
| June 30, 2025 | $704.0K | -26.1% | -27.6% |
| March 31, 2025 | $973.0K | +7.4% | +7.2% |
| September 30, 2024 | $908.0K | -9.0% | -4.6% |
| June 30, 2024 | $952.0K | +37.4% | +5.1% |
| March 31, 2024 | $906.0K | -28.5% | -9.2% |
| September 30, 2023 | $998.0K | -53.7% | +44.0% |
| June 30, 2023 | $693.0K | -50.9% | -45.3% |
- Aspira Women’s Health Inc. showed a decrease of -19.1% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2024 period, Aspira Women’s Health Inc.’s r&d expense has declined by 15.1% (from $3.85 million to $3.27 million).
- The most recent figure is from Aspira Women’s Health Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: